Trv Gp Iii, LLC Jounce Therapeutics, Inc. Transaction History

Trv Gp Iii, LLC

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2021 Feb 14, 2022	SELL	$7.11 - $9.64 $13.5 Million - $18.3 Million	-1,900,000 Reduced 62.32%	1,148,780 $9.59 Million
Q4 2017 Feb 13, 2018	BUY	$12.52 - $17.82 $38.2 Million - $54.3 Million	3,048,780	3,048,780 $38.9 Million

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Trv Gp Iii, LLC, based on Form 13F filings with the SEC.

Stay updated on Trv Gp Iii, LLC with notifications on news.